A retrospective study to determine experience with ICIs used after allogeneic hematopoietic stem cell transplantation in AML/MDS patients with a focus on impact of post-transplant cyclophosphamide
Latest Information Update: 08 Jan 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Cyclophosphamide
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 08 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology